TABLE 2.
Demographic data and details of cancer diagnosis and therapy
| N (98) | % | |
|---|---|---|
| Age group, years | ||
| <5 | 16 | 16.3 |
| 5.1‐10 | 20 | 20.4 |
| 10.1‐15 | 25 | 25.5 |
| 15 or older | 37 | 37.8 |
| Race/ethnicity | ||
| White | 25 | 25.5 |
| Hispanic or Latino | 54 | 55.1 |
| Black or African American | 13 | 13.3 |
| Asian or Pacific Islander | 6 | 6.1 |
| Other | 7 | 7.1 |
| Gender | ||
| Male | 69 | 70.4 |
| Female | 29 | 29.6 |
| Age‐adjusted BMI | ||
| Underweight | 10 | 10.2 |
| Healthy | 51 | 52.0 |
| Overweight | 15 | 15.3 |
| Obese | 22 | 22.4 |
| Comorbidities | ||
| Diabetes | 2 | 2.0 |
| Hypertension | 7 | 7.1 |
| Smoking/vaping | 0 | 0 |
| Asthma | 7 | 7.1 |
| Obesity | 22 | 22.4 |
| None | 51 | 52.0 |
| Other* | 22 | 22.4 |
| Cancer diagnosis | ||
| Leukemia‐ALL | 52 | 53.0 |
| Leukemia‐AML | 9 | 9.2 |
| Lymphoma | 3 | 3.1 |
| CNS tumor | 9 | 9.2 |
| Neuroblastoma | 5 | 5.1 |
| Solid tumor | 16 | 16.3 |
| Other | 4 | 4.1 |
| Diagnosis etiology | ||
| Initial diagnosis | 73 | 74.5 |
| Relapse/refractory | 25 | 25.5 |
| Immunosuppression score # | ||
| Mild | 45 | 45.9 |
| Moderate | 21 | 21.4 |
| Severe | 32 | 32.7 |
| Additional cancer therapy | ||
| Immunotherapy | 10 | 10.2 |
| Autologous HSCT | 5 | 5.1 |
| Allogeneic HSCT | 3 | 3.1 |
| Radiation therapy | 2 | 2.0 |
| Cancer‐directed surgery | 3 | 3.1 |
Patient demographic and diagnosis information is included above. For race/ethnicity and comorbidities, sites were allowed to select all that applied. Age‐adjusted BMI group was assigned by reviewing the patients' biological gender, BMI and age and categorized based on CDC guidelines.
*Other comorbidities included pulmonary metastases, GVHD, renal insufficiency, trisomy 21, hydrocephalus, Soto syndrome, adrenal insufficiency, DVT, bronchiolitis obliterans, history of MAS (Perforin A91V mutation).
#Immunosuppressive score was assigned based on degree of immunosuppression for each patients' course of chemotherapy as outlined in supplemental methods.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.